Physician profile
Colin Cunningham
NPI 1831726819
$510.92
in general payments reported to CMS, 2019-2025
12 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $55.95 · 2024: $230 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $120.25 | 2025 | Brukinsa |
| Tempus Ai, INC | $120.09 | 2024 | |
| Tersera Therapeutics LLC | $64.02 | 2025 | Zoladex |
| Astrazeneca Pharmaceuticals Lp | $44.63 | 2023-2024 | Enhertu |
| Daiichi Sankyo INC. | $26.11 | 2024 | Injectafer |
| Aveo Pharmaceuticals, INC. | $24.26 | 2025 | |
| Sobi, INC | $23.29 | 2023 | |
| Lilly USA, LLC | $23.27 | 2024 | Verzenio, Retevmo, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $17.16 | 2024 | Alunbrig |
| Janssen Biotech, INC. | $16.69 | 2025 | Talvey |
| Beigene USA, INC. | $16.27 | 2024 | Brukinsa |
| Emd Serono, INC. | $14.88 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.